fractory ASUC may be improved with novel infliximab dosing strategies, use of cyclosporin as a bridge to slower acting biologic agents and Janus kinase (JAK) inhibitors as sequential therapy. [8][9][10][11] In this review, we provide an overview of the traditional rescue therapies available in ASUC and mechanisms of failure of rescue therapies. We then summarize and synthesize the emerging literature on contemporary approaches to clinical management of ASUC in the setting of failure to respond to traditional rescue therapies.
SEARCH STRATEGYReferences for this review were identified through electronic searches of Ovid Medline and EMBASE (inception to December 2023), and conference proceedings identified using EM-BASE (January 2020 to December 2023). The following search terms were used alone or in combination: "acute severe colitis, " "ASUC, " "ulcerative colitis, " "hospital, " "severe, " "infliximab, " "cyclosporin, " "ciclosporin, " "tofacitinib, " "upadacitinib, " "vedolizumab", or "ustekinumab. " Only papers published in English were reviewed. The final reference list was generated based on originality and relevance to the scope of this review.